Acute lung allograft dysfunction (ALAD)

Summary

The abstract of the review by Burman and colleagues recognises acute lung allograft dysfunction (ALAD) as a heterogeneous syndrome. The authors describe it as an opportunity to characterise graft injury before irreversible fibrosis develops. This record is held in the stages kind as an early-window object. The abstract gives no diagnostic criteria, thresholds or timing, and none are stated here. Only the abstract of the source review was read; the full text was not read.

Sources and links

• Burman et al. 2026, J Heart Lung Transplant (DOI; abstract only was read) (primary)
• PubMed record (PMID 42854767)

Related

Links from this record

• described in (abstract only): CLAD: translating basic science to clinical practice

Linked from (derived)

• early window discussed: Molecular endotypes of CLAD (proposed framework)
• studies: Persistent and progressive acute lung allograft dysfunction is linked to cell compositional and transcriptional changes in small airways
• discusses: CLAD: translating basic science to clinical practice
• supports: Macrophage and CD8 T cell discordance are associated with acute lung allograft dysfunction progression
• discusses: Interferon-stimulated and metallothionein-expressing macrophages are associated with acute and chronic allograft dysfunction after lung transplantation
• describes risk for: Emergence of a senescent and inflammatory pulmonary CD4+ T cell population prior to lung allograft failure
• defines: The ABC of transplant: ALAD, BLAD, and CLAD: definition and significance
• affects: Definitions and prognosis of ALAD and BLAD are not settled

Known gaps in this record

• full text of the source review not read, so the evidence, citations and level of agreement for this item are missing
• funding and conflicts of interest of the source review not read
• diagnostic criteria, thresholds and timing of ALAD not recorded